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fluctuating renal function and the 
risk of incident atrial fibrillation: a 
nationwide population-based study
Soonil Kwon1,6, So-Ryoung Lee1,6, Eue-Keun choi1*, Kyung-Do Han2, Seokhun Yang  1, 
Seo-Young Lee1, Hyun-Jung Lee1, Inki Moon1, Euijae Lee1, Myung-Jin cha1, Woo-Hyun Lim3, 
Seil oh  1 & Gregory Y. H. Lip  4,5
Although chronic kidney disease is known to increase the risk of atrial fibrillation (AF), the impact of the 
variability of renal function on the risk of incident AF is unknown. We aimed to evaluate the association 
between variability of renal function and the risk of developing AF among the general population. We 
evaluated a total of 3,551,249 adults who had three annual health check-ups provided by the National 
Health Insurance Service. The variability of renal function was defined as GFR-VIM, which is variability 
independent of the mean (VIM) of creatinine-based estimated glomerular filtration rate (eGFR). The 
study population was divided into four groups (Q1-4) based on the quartiles of GFR-VIM, and the risks 
of incident AF by each group were compared. During a mean of 3.2 ± 0.5 years follow-up, incident AF 
occurred in 15,008 (0.42%) subjects. The incidence rates of AF increased from Q1 to Q4 (0.98, 1.42, 
1.27, and 1.63 per 1,000 person-years, respectively). Adjusting with multiple variables, Q4 showed 
an increased risk of incident AF compared to Q1 (hazard ratio (HR) 1.125, 95% confidence interval 
(CI) 1.071–1.181). Variability of serum creatinine or other definitions of variability showed consistent 
results. On subgroup analyses, Q4 in males or those with a decreasing trend of eGFR had significantly 
increased risks of incident AF compared to Q1 (HR 1.127, 95% CI 1.082–1.175; and HR 1.115, 95% CI 
1.059–1.173, respectively). High variability of eGFR was associated with an increased risk of incident AF, 
particularly in males or those with decreasing trends of eGFR during follow-up.
The prevalence of atrial fibrillation (AF) is increasing and is most frequently confronted arrhythmia in clinical 
practice1–3. Considering the impact of thromboembolism and mortality in patients with AF, long-term outcomes 
might be improved by suspecting silent AF, documenting the disease, and initiating appropriate management 
among a high-risk population4–6. Many risk factors are known to contribute to AF development7, but it is also 
essential to uncover and manage modifiable risk factors for incident AF8.
AF and renal functions are intimately interlinked with each other9–14. Multiple prospective studies have found 
that individuals with chronic kidney disease (CKD) have a higher risk of incident AF10,12–14. Other studies evalu-
ated that not only the presence of CKD but also estimated glomerular filtration rate (eGFR) were associated with 
the risk of developing AF9,10. Conversely, AF also increases the risk of renal dysfunction11,14. However, one caveat 
is that renal function in most prior studies was ‘one-off ’ assessments at baseline, often inferred by measuring 
(single) serum creatinine or cystatin c levels, despite the known visit-to-visit variability15,16. This renders an inter-
pretation of the risk of AF to be difficult, especially among the individuals with high variability of renal function.
High variability of eGFR is known to increase the risk of progression or mortality of CKD17,18. However, there 
is a paucity of information on the association between variability of renal function and the risk of developing AF. 
Therefore, in this study, we investigated the impact of visit-to-visit variability of eGFR on the risk of incident AF 
among the general population using a nationwide population-based cohort.
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Results
During a mean of 3.2 ± 0.5 years of follow-up, AF occurred in 15,008 (0.42%) patients (incident rate = 1.33 per 
1,000 person-years). The mean age of the total population was 44.2 years, and 68.5% were males. Characteristics 
of the study population categorized by the quartiles of variation independent of the mean of eGFR (GFR-VIM) 
are presented in Table 1. Compared to the individuals with the lowest eGFR variability (Q1), those with the high-
est eGFR variability (Q4) were older (mean age 46.9 vs. 40.8 years), less often male (57.3 vs. 83.9%), less smokers 
(current smoker 24.8 vs. 39.1%), less drinking (heavy drinking 6.8 vs. 10.2%), and having lower incomes (low 
income proportion 21.5 vs. 10.7%). All comorbidities were more prevalent in individuals with the highest eGFR 
variability (Q4).
Compared to Q1, Q4 had more CKD (8.6 vs. 0.6%), hypertension (23.4 vs. 16.0%), and dyslipidemia (22.3 vs. 
15.5%). While there was no difference in mean creatinine in both groups (0.92 ± 0.15 in Q1 vs. 0.93 ± 0.31 mg/
dL in Q4), there was a substantial difference in the baseline eGFR (90.67 ± 15.33 in Q vs. 86.84 ± 24.26 mL/
GFR-VIM
p-value
Q1 Q2 Q3 Q4
N = 887,995 N = 887,624 N = 887,756 N = 887,874
Demographics
Age (year) 40.82 ± 10.33 46.22 ± 11.3 43.08 ± 11.19 46.86 ± 11.56 <0.0001
Age strata <0.0001
   20–39 (year) 438,073 (49.33) 250,892 (28.27) 364,998 (41.11) 247,700 (27.9)
   40–64 (year) 434,086 (48.88) 591,761 (66.67) 490,033 (55.2) 582,630 (65.62)
   ≥65 (year) 15,836 (1.78) 44,971 (5.07) 32,725 (3.69) 57,544 (6.48)
Male 745,029 (83.9) 470,308 (52.99) 709,076 (79.87) 508,415 (57.26) <0.0001
Weight (kg) 69.86 ± 12.24 64.38 ± 11.91 69.08 ± 12.22 65.71 ± 12.28 <0.0001
Height (cm) 169.88 ± 7.9 164.75 ± 8.45 168.94 ± 7.97 165.2 ± 8.97 <0.0001
Waist circumference (cm) 81.87 ± 8.89 79.33 ± 9.42 81.77 ± 9.04 80.47 ± 9.27 <0.0001
Body mass index (kg/m2) 24.11 ± 3.31 23.61 ± 3.28 24.1 ± 3.3 23.96 ± 3.28 <0.0001
Health habits
Smoking status <0.0001
   Never smoker 349,782 (39.39) 534,573 (60.23) 370,258 (41.71) 510,642 (57.51)
   Ex-smoker 191,405 (21.55) 160,314 (18.06) 200,448 (22.58) 156,987 (17.68)
   Current smoker 346,808 (39.06) 192,737 (21.71) 317,050 (35.71) 220,245 (24.81)
Alcohol consumption <0.0001
   Never drinker 278,963 (31.41) 404,565 (45.58) 304,697 (34.32) 415,451 (46.79)
   Mild drinker 518,464 (58.39) 429,305 (48.37) 498,177 (56.12) 412,421 (46.45)
   Heavy drinker 90,568 (10.2) 53,754 (6.06) 84,882 (9.56) 60,002 (6.76)
   Regular exercise 205,801 (23.18) 208,041 (23.44) 213,473 (24.05) 211,217 (23.79) <0.0001
Low income status 95,216 (10.72) 147,820 (16.65) 124,675 (14.04) 190,996 (21.51) <0.0001
Comorbidities
Chronic kidney disease 5,439 (0.61) 19,810 (2.23) 21,577 (2.43) 76,346 (8.6) <0.0001
Diabetes 53,128 (5.98) 64,930 (7.32) 66,080 (7.44) 79,255 (8.93) <0.0001
Hypertension 142,213 (16.02) 176,333 (19.87) 169,374 (19.08) 207,503 (23.37) <0.0001
Dyslipidemia 137,710 (15.51) 168,229 (18.95) 156,547 (17.63) 197,614 (22.26) <0.0001
Laboratory results†
Serum creatinine (mg/dL) 0.92 ± 0.15 0.88 ± 0.18 0.93 ± 0.16 0.93 ± 0.31 <0.0001
eGFR (mL/min/1.73 m²) 90.67 ± 15.33 84.18 ± 16.28 89.13 ± 18.75 86.84 ± 24.26 <0.0001
Fasting glucose (mg/dL) 97.09 ± 20.5 97.48 ± 20.67 97.99 ± 21.75 98.48 ± 22.7 <0.0001
Systolic blood pressure (mmHg) 121.98 ± 12.85 120.35 ± 13.69 121.86 ± 13.15 121.31 ± 13.68 <0.0001
Diastolic blood pressure (mmHg) 76.83 ± 9.13 75.64 ± 9.46 76.68 ± 9.26 76.07 ± 9.45 <0.0001
Total cholesterol (mg/dL) 193.8 ± 35.06 194.34 ± 35.34 193.76 ± 35.46 195.32 ± 36.56 <0.0001
HDL (mg/dL) 53.87 ± 14.31 56.4 ± 14.91 54.3 ± 14.19 55.85 ± 14.66 <0.0001
LDL (mg/dL) 113.69 ± 39 114.03 ± 36.75 113.23 ± 41 114.14 ± 40.82 <0.0001
Triglyceride‡ (mg/dL) 117.48 (117.34–117.63)
105.07 
(104.94–105.2)
116.86 
(116.71–117)
111.97 (111.83–
112.11) <0.0001
Table 1. Baseline characteristics of the study population by the quartiles of GFR-VIM*. Abbreviation: 
eGFR = estimated glomerular filtration rate calculated by MDRD equation; GFR-VIM = variability independent 
of mean of eGFR; HDL = high-density lipoprotein; LDL = low-density lipoprotein; Q1-4 = the 1st ~ 4th quartiles 
of GFR-VIM. *GFR-VIM was calculated by 100 x SD/meanβ, where β is the coefficient derived from curve 
fitting of eGFRs. †All the values except triglyceride are presented as mean ± SD. ‡Presented as geometric mean 
with interquartile range.
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min/1.73 m² in Q4). For other laboratory findings, subjects with Q4 had higher blood pressure, fasting serum glu-
cose, and cholesterol levels compared with Q1. All comparisons showed statistical significance (p-values < 0.0001) 
due to the large numbers of the study population.
GFR Variability and the Risk of AF. The Kaplan-Meier survival curves and Cox regression analysis of 
incident AF by the quartiles of GFR-VIM are presented in Fig. 1. Compared to the individuals with the lowest 
quartile of GFR-VIM (Q1), those with the highest quartile of GFR-VIM (Q4) had higher crude incidence rates. 
Figure 2 and Supplementary Table S1 shows both incidence rates and risks of AF by quartiles of GFR-VIM. The 
incidence rate of AF increased from 0.98 to 1.63 per 1,000 person-years. In multivariate analysis adjusted for age, 
sex, smoking status, alcohol consumption, regular physical activity, low income level, body-mass index, hyper-
tension, diabetes, and baseline eGFR, the risk of incident AF was also higher in the Q4 than Q1 (adjusted hazard 
ratio (HR) 1.125, 95% confidence interval (CI) 1.071–1.181, p-value < 0.001). For the individuals with a middle 
range of GFR-VIM (Q2 and Q3), there were no significant differences in AF risk compared to Q1 (adjusted HR 
1.042, 95% CI 0.991–1.095 for Q2, adjusted HR 1.041, 95% CI 0.990–1.094 for Q3, all calculated by Model 2).
We analyzed the association between eGFR variability and incidence rate and the risk of AF by decile of 
eGFR (Supplementary Table S2 and Supplementary Fig. S1). There was a positive correlation between eGFR 
Figure 1. The cumulative incidences of incident atrial fibrillation by the quartiles of GFR-VIM. Compared 
to the individuals with the lowest variability of renal function (Q1), those with the highest variability of renal 
function (Q4) had higher crude incidence rates of atrial fibrillation. Abbreviation: AF = atrial fibrillation; 
eGFR = estimated glomerular filtration rate calculated by MDRD equation; GFR-VIM = variability independent 
of mean of eGFR.
Figure 2. The risks of incident atrial fibrillation by the quartiles of GFR-VIM. With an adjusted model, the 
risk of incident AF was significantly increased in the group with the highest variability of renal function (Q4). 
For the individuals with a middle range of GFR-VIM (Q2 and Q3), there were no significant differences in AF 
risk compared to the group with the lowest variability of renal function (Q1). Abbreviation: CI = confidence 
interval; AF = atrial fibrillation; eGFR = estimated glomerular filtration rate calculated by MDRD equation; 
GFR-VIM = variability independent of mean of eGFR; HR = hazard ratio, adjusted by Model 2 (age, 
sex, smoking status, alcohol consumption, regular physical activity, low income level, body-mass index, 
hypertension, diabetes, and baseline eGFR); IR = incidence rate in 1,000 person-years.
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variability and the risk of developing AF. Compared to the individuals with the 1st decile of GFR-VIM, those with 
higher than 7th decile of GFR-VIM had a significantly higher risk of AF. Observing the trend of HRs by deciles of 
GFR-VIM, the individuals with extreme variability of eGFR (those with the 9th and the last decile of GFR-VIM) 
were at the highest risk of incident AF (adjusted HR 1.176 and 1.202 respectively).
Subgroup analyses. Most subgroup analyses showed consistency with the main results, whereas age strata, 
sex, and eGFR trends showed significant interactions (Fig. 3 and Supplementary Table S3). For the subgroups of 
age strata, an increasing trend for developing AF risk was observed in older subjects (adjusted HR 1.030, 95% CI 
0.919–1.155 for 20–39 years; adjusted HR 1.078, 95% CI 1.032–1.126 for 40–64 years; and adjusted HR 1.168, 95% 
CI 1.082–1.260 for ≥65 years, where Q1–3 of each age stratum served as a reference, p-for-interaction = 0.0153). 
Males showed a higher risk of AF in those with higher eGFR variability (adjusted HR 1.127, 95% CI 1.082–1.175 
for male Q4, where male Q1-3 served as a reference, p-for-interaction = 0.0003), whereas female did not. Among 
the subgroups by eGFR trends, subjects with a decreased eGFR trend had a significantly higher risk of AF in those 
with the highest eGFR variability (Q4), whereas those with maintained eGFR or increased eGFR trends showed a 
trend for increased risk of AF in those with the highest eGFR variability (Q4).
Sensitivity analyses. To observe the consistent association between eGFR variability and AF risk, we cal-
culated variability by standard deviation (SD), coefficient of variation (CV), and average real variability (ARV) 
Figure 3. The risks of incident atrial fibrillation by various subgroups. Most subgroup analyses showed 
consistency with the main results, whereas age strata, sex, and eGFR trends showed significant interactions. 
For the subgroups of age strata, an increasing trend for developing AF risk was observed in older subjects. 
Males showed a higher risk of AF in those with higher eGFR variability. Among the subgroups by eGFR 
trends, only the subjects with a decreased eGFR trend had a significantly higher risk of AF in those with higher 
eGFR variability. Abbreviation: AF = atrial fibrillation; CI = confidence interval; CKD = chronic kidney 
disease; eGFR = estimated glomerular filtration rate calculated by MDRD equation; GFR-VIM = variability 
independent of mean of eGFR; HR = hazard ratio, adjusted by Model 2 (age, sex, smoking status, alcohol 
consumption, regular physical activity, low income level, body-mass index, hypertension, diabetes, and baseline 
eGFR); IR = incidence rate in 1,000 person-years. *Each subgroup represents the 4th quartile of GFR-VIM with 
a suggested condition, whereas the corresponding lower three quartiles served as a reference. †Individuals with 
decreased or increased eGFR trends were defined as the subgroups with the last eGFR lower or higher than 5% 
of the mean. Other cases were identified as maintained.
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(Supplementary Table S4 and Supplementary Fig. S2). The eGFR variability of the three methods was categorized 
into quartiles and calculated the risk of AF. In line with the variability independent of the mean (VIM) method, 
individuals with the highest variability had a significantly higher chance of AF than those with the lowest variabil-
ity (adjusted HR 1.102, 95% CI 1.051–1.157 for SD; adjusted HR 1.137, 95% CI 1.085–1.191 for CV; and adjusted 
HR 1.100, 95% CI 1.048–1.153 for ARV, all in Model 2). Also, the variability of serum creatinine was calculated 
to remove the possible bias of age and sex (Supplementary Table S5 and Supplementary Fig. S3). Creatinine var-
iability showed consistent results with increased risk of AF in the highest variability (adjusted HR 1.136, 95% CI 
1.084–1.189 for SD, adjusted HR 1.133, 95% CI 1.081–1.187 for CV, adjusted HR 1.108, 95% CI 1.054–1.164 for 
VIM; and adjusted HR 1.106, 95% CI 1.060–1.155 for ARV, all in Model 2). The subjects with the highest varia-
bility showed a consistent increased risk of AF independent of the methods of variability, statistical models, or 
renal function measurements.
To adjust with the baseline renal function, we analyzed the association of the eGFR variability and the 
risk of AF according to baseline eGFR (eGFR ≥90, 60-89, <60 mL/min/1.73 m², Supplementary Table S6 and 
Supplementary Fig. S4). The number of events was 4,313 (28.74%), 9,507 (63.35%), and 1,188 (7.92%) in each 
subgroup respectively. After adjusted with other variables, individuals with the highest GFR-VIM showed an 
increased risk of AF only in those with eGFR 60–89 mL/min/1.73 m² (adjusted HR 1.106, 95% CI 1.039–1.177).
To remove the potential causality between AF and GFR variability, we censored incident AF that occurred 
within the first year of follow-up (Supplementary Table S7). In this sensitivity analysis, an additional 8.4% of AF 
risk was observed in those with the highest GFR-VIM (adjusted HR 1.084, 95% CI 1.024–1.149 for Q4). Although 
this risk was less than the result without censoring (HR 1.125, 95% CI 1.071–1.181), patients with the highest 
renal variability consistently showed a higher risk of AF.
Discussion
To the best of our knowledge, this is the first report on evaluating the impact of the variability of renal functions 
on the risk of AF. The main findings of our study are as follows: (1) higher variability of eGFR was associated with 
an increased risk of incident AF, which was consistent regardless of methods of variability and metrics of renal 
function; and (2) the impact of variability of eGFR on the risk of AF only existed in males, age ≥40 years, or those 
with a decreasing eGFR trend.
Several studies have shown that impaired renal function was a risk factor of AF10,12–14. Watanabe et al. found 
subject with cystatin C-based eGFR <30 mL/min/1.73 m² had a 32% increased risk of AF compared to those with 
eGFR 30–59 mL/min/1.73 m² 14. Another prospective study showed that women had a significantly higher risk 
of AF (HR 1.36, 95% CI 1.00–1.84) only when there was severe impairment of renal function (cystatin C-based 
eGFR < 60 mL/min/1.73 m²)19. Also, Horio et al. demonstrated CKD was a powerful predictor of new-onset 
AF (HR 2.18), independent of left ventricular hypertrophy or left atrial dilatation12. According to a previous 
meta-analysis, eGFR < 60 mL/min/1.73 m² was the cut-off value which was associated with an increased risk of 
incident AF10. Across five categories of decreasing eGFR (≥90 (reference), 60–89, 45–59, 30–44, and <30 mL/
min/1.73 m²), there was a stepwise increase in the risk of AF in the last three groups, but not in the group with 
eGFR 60–89 L/min/1.73 m² (HR 1.09, 95% CI 0.97–1.24)10.
Not only does the risk of AF increased according to renal dysfunction, but there is also evidence that 
new-onset AF increased the risk of renal dysfunction11,14. The presence of AF has been associated with the devel-
opment of renal dysfunction (HR 1.77, 95% CI 1.50–2.10)14. The impact of AF on renal dysfunction was only 
observed in those with CKD11. Therefore, the association between AF and renal dysfunction seems to be bidirec-
tional. This suggests that AF and CKD share many common pathophysiological processes. Of the latter, activation 
of the renin-angiotensin-aldosterone system (RAAS) can be considered first. The use of angiotensin-converting 
enzyme inhibitors or angiotensin receptor blockers in CKD patients has been reported to be effective in slowing 
the progression of CKD since RAAS is overtly activated in CKD20. Likewise, there are reports that RAAS also 
mediates AF development21, suggesting that exacerbation of RAAS may be associated with the progression of 
both diseases. Second, inflammation can be another mechanism in the progression of both diseases. In CKD, 
inflammatory indicators such as C-reactive protein and fibrinogen are elevated22, and this inflammatory milieu 
can affect the development of AF by mediating local inflammation in the left atrium23.
Recently, eGFR variability has attracted attention as a factor affecting renal function17. Fluctuating levels of 
serum creatinine, which changes nonlinearly like a saw-tooth, is known to have a detrimental effect on CKD pro-
gression and prognosis24. Unlike the decline in renal function, the impact of variability in renal function on AF 
is less known. Although the mechanism between the variability of renal function and AF is not well understood, 
other studies have reported that the variability of various metabolic indicators can be related to incident AF25,26. 
Based on previous reports, we would expect that variability in renal function would be associated with AF, pro-
vided that CKD and AF share some pathophysiological mechanisms. Also, we could hypothesize that high vari-
ability of renal function would be associated with AF development by promoting CKD and exacerbating RAAS 
modulation. Further large studies are needed to elucidate the associated mechanisms and causal associations.
There are several limitations to be noted. First, the cause of higher eGFR variability is unclear. Since our 
study used serum creatinine to calculate eGFR, any causes, such as fluctuating muscle mass, related to creatinine 
variability could influence eGFR variability. Second, a causal relationship between eGFR variability and incident 
AF needs more evidence given the observational design of our study. However, the sensitivity analysis to min-
imize the effects of reverse causality by excluding individuals with incident AF occurring within the first year 
showed consistent with the main results. Third, there was no data with cystatin C or combined creatinine-cystatin 
C-based eGFR, which is more accurate than the Modification of Diet in Renal Disease Study Group (MDRD) 
based eGFR27. This is an inherent limitation of the claims database of the National Health Insurance Service 
(NHIS) since it measures eGFR based on serum creatinine. Fourth, possible selection bias may originate from 
choosing the study population based on the number of health check-ups, since more regularly examined 
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individuals may be prone to pay more attention to their health status. Also, there exists an inter-laboratory varia-
tion of serum creatinine measurement due to different calibration settings. Lastly, it would be difficult to confirm 
whether those with acute renal failure were excluded from the analysis. The health check-ups were performed 
in the outpatient clinic, so those currently being admitted to hospital for acute or chronic illness could not be 
enrolled. Therefore, we assumed that the cases of acute illness such as sepsis and other rapidly progressing acute 
kidney injury are extremely limited in this study.
In this nationwide population-based study, high eGFR variability was associated with an increased risk of 
incident AF. This was consistently observed across different methods of variability after adjusting potential con-
founders such as baseline eGFR. This association was particularly evident in males or those with decreasing 
trends of eGFR during follow-up.
Methods
The NHIS of Korea was the source of the claims database used in the study. This claims database encom-
passes information of demography, prescription, procedures, and the diagnostic codes which are encoded in 
the International Classification of Disease, Tenth Revision, Clinical Modification. Since the NHIS is the single 
national insurer in Korea, it covers virtually all Koreans. Therefore, its database can represent comprehensive 
medical coverage of the entire Korean population. Since all the data are anonymized and can be accessed by 
researchers for public health studies, informed consent was exempted by the review board. The study protocol 
was approved by the Seoul National University Hospital Institutional Review Board (IRB No. 1811-132-987). All 
research was performed in accordance with relevant guidelines and regulations.
Study design. The flow chart of the study population is presented in Fig. 4. For each who had health 
check-ups provided by the NHIS, the index date was set to be the date of the health check-up during 2014–2015. 
There was a total of 19,357,573 subjects who had a health check-up during 2014–2015. There were two categories 
of serum creatinine measurements during the health check-ups; an isotope dilution mass spectrometry (IDMS) 
method and a non-IDMS one. We excluded those who had less than three check-ups during 2012–2015 or those 
who measured serum creatinine by non-IDMS for the coherence of the analysis (excluding n = 15,751,322). Also, 
we excluded those aged less than twenty years (n = 406) or those with missing measurements of the variables 
(n = 17,337). Finally, we excluded those who had AF before the index date (n = 39,259). As a result, a total of 
3,551,249 individuals were analyzed in our study. This population then categorized into four groups by quartiles 
of VIM28 of eGFR. From the lowest to the highest quartiles of GFR-VIM, the groups were named as Q1 to 4 
accordingly.
Definitions of measurements and variability. During the health check-up, every individual measured 
serum creatinine, and eGFR was calculated by a creatinine-based equation used from MDRD29. Other varia-
bles including blood pressure, cholesterol level, and fasting blood glucose were also measured. A standardized 
questionnaire by the NHIS evaluated individual health habits such as smoking status, alcohol consumption, and 
physical activities. Details of each question are listed in Supplementary Table S8. For comorbidities, we included 
hypertension, diabetes, dyslipidemia, and CKD, which were defined by operational definitions using diagnostic 
codes. Supplementary Table S9 summarizes the detailed definitions of the comorbidities used in the study. To 
define the individual variability of renal function, we used at least three eGFR values obtained from serial health 
check-ups. VIM was chosen to represent eGFR variability and was calculated as 100 x SD/meanβ, where β is the 
coefficient derived from curve fitting using PROC NLIN procedure of the SAS package28,30.
Study outcomes and follow-up. Incident AF, the primary outcome in this study, was defined as patients 
who had diagnostic codes of I48.0–48.4 or I48.9 during hospitalization or visiting the outpatient clinic more than 
2 times. The index date was the date of the last health check-up during 2014–2015. The follow-up period was set 
from the index date to the time of incident AF or until December 31, 2018, whichever came first.
Statistical analysis. For the Q1-4 quartiles of GFR-VIM, we used one-way analysis of variance and Pearson’s 
chi-square test to compare baseline characteristics. Incidence rates of AF were calculated as the number of events 
divided by 1,000 person-years during the follow-up. The survivals of the four groups were compared by the 
Figure 4. The flow chart of the study population. A total of 3,551,249 individuals were analyzed in the 
study. This population then categorized into the four groups by quartiles of GFR-VIM. Abbreviation: 
eGFR = estimated glomerular filtration rate calculated by MDRD equation; GFR-VIM = variability independent 
of mean of eGFR; IDMS = isotope dilution mass spectrometry; NHIS = national health insurance service.
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Kaplan-Meier analysis using log-rank tests. The risks of incident AF by the groups were evaluated by multivariate 
Cox proportional hazards regression models. The statistical model was adjusted for age, sex, smoking status, alco-
hol consumption, exercise habit, income level, body mass index (BMI) (Model 1), or further by the baseline eGFR 
and comorbidities including hypertension and diabetes (Model 2). We also re-categorized the study population in 
deciles of GFR-VIM to analyze trends between eGFR variability and incident AF risk. All the statistical analyses 
were performed in two-sided, and the statistical significance was defined as p-values of < 0.05. We performed 
statistical analyses with SAS 9.3 (SAS Institute Inc., Cary, North Carolina, USA).
Subgroup analyses. Additional analyses of comparing the risks of AF between the Q4 versus Q1-3 (refer-
ence) were performed with the following subgroups: age strata (20–39, 40–64, and ≥65 years), sex, BMI (<18.5, 
18.5–25, ≥25 kg/m2), comorbidities (CKD, hypertension, diabetes, and dyslipidemia), smoking status, and eGFR 
trends. The eGFR trends were grouped into three categories (decreased, maintained, and increased). Individuals 
with decreased or increased categories were those with the last eGFR lower or higher than 5% of the mean. The 
subgroup analyses were performed with multivariate Cox proportional hazards regression models with the same 
variables used in the main analysis. The statistical significance of the p-value between each group was defined as 
p-for-interaction of <0.1.
Sensitivity analyses. To observe a consistent association between eGFR variability and incident AF risk, 
we calculated the variability by three other methods; SD, CV, and ARV31. Q1-4 categories were re-defined by the 
quartiles of each definition of variability, and multivariate Cox proportional hazards regression analyses were 
compared to each other. To remove the possible non-renal bias of eGFR, which incorporates variables including 
sex and age altogether, we calculated creatinine variability. Creatinine variability was calculated by VIM, SD, CV, 
and ARV. Cox proportional hazards regression analyses of accordingly categorized Q1-4 for each definition of 
creatinine variability were compared to each other. To observe whether the association between eGFR variability 
and incident AF risk was able to be reproduced in different classes of renal function, we performed additional 
sensitivity analysis. For the latter, the study population was divided into three groups by the baseline eGFR (<60, 
60–89, and ≥90 mL/min/1.73 m²), and the Q1-4 for each group were re-defined by the quartiles of GFR-VIM of 
each class. Lastly, we performed another sensitivity analysis to remove the possible causal relationship between 
AF and eGFR variability. In this analysis, incident AF events that occurred within the first year were censored.
Data availability
The datasets generated and/or analyzed during the current study are not publicly available due to the national 
security policy on the health data of the NHIS.
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